STAT@ASH: Final Agenda Announced—Last Call to RSVP to Attend on Dec. 7

UPCOMING EVENT

Final Agenda Announced — Last Call to RSVP

Join us next week at STAT@ASH: From Sickle Cell to Cancer in San Diego to explore pressing issues and breakthroughs in hematology.

Why this is a can't miss event:

Hesham Ahmed Abdullah of GSK and Mark Wildgust of Johnson & Johnson Innovative Medicine join our lineup alongside executives from AstraZeneca and Regeneron to discuss how new technologies—such as bispecific antibodies, antibody-drug conjugates, and precision medicines—are reshaping the way hematological cancers are treated.

The event will also feature a panel, moderated by STAT's Adam Feuerstein, on the state of sickle cell treatment, exploring the challenges and opportunities posed by groundbreaking gene-editing therapies and the withdrawal of Oxbryta—an important look at what's next for the field.

Plus, connect with other leaders in hematology. We hope to see you there!

- The STAT Events Team

REGISTER NOW